Universitaetsklinikum Aachen AöR

4 trials 2 recruiting Academic / non-commercial

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

2 Countries active

5 Unique IMPs

100% Results reported

Phase II

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioma 1 Septic shock 1 Sepsis 1 Hepatic cirrhosis 1

Top IMPs

FLUCICLOVINE (18F) 1 FLUOROETHYLTYROSINE F-18 1 IMMUNOGLOBULIN A, IMMUNOGLOBULIN G, IMMUNOGLOBULIN M 1 INTESTIFIX 1 RUXOLITINIB 1

All trials

4 total

Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, doubl… Recruiting

2023-507790-18-00 Phase II 1 country INTESTIFIX
Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonit… Recruiting

2024-513526-27-00 Phase II 2 countries IMMUNOGLOBULIN A, IMMUNOGLOBULIN G, IMMUNOGLOBULIN M
Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA… Ended

2024-515619-23-00 Phase II 1 country RUXOLITINIB
Comparison of 18F-Fluciclovine PET versus 18F-Fluoroethyltyrosine PET in patients with newly diagnosed cerebral gliomas, recurrent cerebral … Ended

2023-507786-26-00 Phase II 1 country FLUCICLOVINE (18F); FLUOROETHYLTYROSINE F-18

Showing 1–4 of 4 trials

← All sponsors A–Z